

# DRUG AND POISON INFORMATION CENTRE

---

## Detail drug information on Suxamethonium chloride

### Response:

**Class:** Musculoskeletal agent, Neuromuscular blocker

### Mechanism of action:

Succinylcholine chloride, an ultra-short acting depolarizing skeletal muscle relaxant, mimics acetylcholine as it binds with the cholinergic receptors on the motor end plate, thus producing a Phase I block as manifested by fasciculations. It may exhibit a nondepolarizing block (Phase II) when its concentration and duration are increased.

### Pharmacokinetics:

#### Distribution:

Succinylcholine primarily distributes to extracellular fluid spaces, with 80% of the drug undergoing hydrolysis before reaching the neuromuscular end-plate

#### Metabolism Sites and Kinetics:

1) BLOOD, rapid

a) Succinylcholine is rapidly hydrolyzed in the plasma by pseudocholinesterase. Only 20% of the administered dose reaches the neuromuscular end-plate.

#### Excretion:

Kidney

1) Renal Excretion (%)

a) 10%

### Dosing:

- A 5- to 10-mg test dose may be used to determine sensitivity of patient and individual recovery time.
- In patients homozygous for the atypical plasma cholinesterase gene, a test dose of 5 to 10 mg may be administered to evaluate sensitivity, or neuromuscular blockade may be produced by a slow IV infusion of 1 mg/mL

- Treat apnea or prolonged muscle paralysis with controlled respiration

### **Adverse effects:**

- **Musculoskeletal:**  
Myalgia (16% to 100%)
- **Ophthalmic:**  
Raised intraocular pressure.

### **USES:**

Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation

### **Contraindications:**

- Hypersensitivity to succinylcholine
- Malignant hyperthermia.
- Skeletal muscle myopathies

### **Drug interactions:**

- Concurrent use of ST JOHN'S WORT and ANESTHETICS may result in an increased risk of cardiovascular collapse and/or delayed emergence from anesthesia.
- Concurrent use of SUCCINYLCHOLINE and PANCURONIUM may result in pancuronium toxicity (respiratory depression, apnea)
- Concurrent use of SUCCINYLCHOLINE and PROMAZINE may result in a prolongation of neuromuscular blockade.

### **Monitoring parameters:**

- facilitation of tracheal intubation and skeletal muscle relaxation during surgery or mechanical ventilation is indicative of efficacy (as adjunct to general anesthesia)
- temperature and expired carbon dioxide; continuously, for early recognition of malignant hyperthermia
- electrocardiogram of pediatric patients for peaked T-waves, an early sign of potential cardiac arrest secondary to acute rhabdomyolysis with hyperkalemia
- neuromuscular function with a peripheral nerve stimulator when administered as an IV infusion.